The Pennant Group, Inc. PNTG R2KR3KPHARMA
Company Overview
The Pennant Group, Inc. provides healthcare services in the United States. It operates in two segments, Home Health and Hospice Services, and Senior Living Services. The company offers home health services, including clinical services, such as nursing, speech, occupational and physical therapy, medical social work, and home health aide services; and hospice services comprising clinical care, education, and counseling services for the physical, spiritual, and psychosocial needs of terminally ill patients and their families. It also provides senior living services, such as residential accommodations, activities, meals, housekeeping, and assistance in the activities of daily living to seniors who are independent or who require some support. The company operates home health, hospice, and home care agencies, as well as senior living communities in Alabama, Arizona, California, Colorado, Idaho, Montana, Nevada, Oklahoma, Oregon, Tennessee, Texas, Utah, Washington, Wisconsin, and Wyoming. The Company was incorporated in 2019 and is headquartered in Eagle, Idaho.
Why Investors Should Care
Net profit has compounded at 14.7% per year over the last five years.
Revenue has grown at a 18.1% CAGR over the past five years.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $947.71M (+36.3% YoY); net profit $29.58M.
- Trailing 12 Months Year-on-year growth — revenue +35.8%, earnings +25.0%.
- 5-Year Trend Long-term compounding — revenue CAGR 18.1%, profit CAGR 14.7%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 18.07% |
| 1 Year: | 35.80% |
Compounded Profit Growth
| 5 Years: | 14.71% |
| 1 Year: | 25.00% |
Stock Price Performance
| 1 Year: | +45.71% |
| 6 Months: | +12.89% |
| 3 Months: | +19.84% |
| 1 Month: | -2.71% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)45.99 · Neutral
P/E of 41.76 is above the sector median of 25.17 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 18.1% over 5 years.
- Profit CAGR of 14.7% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | PNTG The Pennant Group, Inc. R2KR3KPHARMA | 38.00 | 41.76 | $1.33B | 0.00% | 6.32% | 10.42% | 18.07% | 14.71% |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | 72.95M | 77.91M | 82.73M | 88.40M | 91.85M | 92.74M | 98.40M | 105.66M | 110.34M | 111.92M | 113.91M | 116.32M | 118.35M | 126.46M | 132.28M | 140.19M | 156.91M | 168.75M | 180.69M | 209.84M | 219.50M | 229.04M | 285.36M | 297.98M |
| Operating Income | - | - | 5.80M | 1.83M | 3.31M | 1.93M | 4.27M | 6.08M | 4.48M | 1.61M | 3.57M | 1.70M | 2.33M | -3.12M | 7.14M | 4.28M | 6.26M | 7.06M | 8.52M | 9.56M | 10.79M | 12.65M | 11.53M | 10.24M | 17.30M | 17.19M |
| Net Income | 3.38M | 4.16M | 4.37M | 1.33M | 3.49M | 1.52M | 2.98M | 4.34M | 4.41M | 950.00K | 2.65M | 1.25M | 1.01M | -2.68M | 4.83M | 1.85M | 2.80M | 4.38M | 4.91M | 5.69M | 6.21M | 7.78M | 7.08M | 6.08M | 8.52M | 9.08M |
| Diluted EPS | - | - | - | 0.05 | 0.13 | 0.06 | 0.10 | 0.15 | 0.15 | 0.03 | 0.09 | 0.04 | 0.03 | -0.09 | 0.16 | 0.06 | 0.09 | 0.15 | 0.16 | 0.18 | 0.20 | 0.22 | 0.20 | 0.17 | 0.24 | 0.25 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 250.99M | 286.06M | 338.53M | 390.95M | 439.69M | 473.24M | 544.89M | 695.24M | 947.71M |
| Operating Income | 15.40M | 20.63M | 5.67M | 18.92M | 4.70M | 12.74M | 25.17M | 38.12M | 51.89M |
| Net Income | 9.87M | 15.68M | 2.55M | 15.74M | 2.70M | 6.64M | 13.38M | 22.56M | 29.58M |
| Diluted EPS | 0.36 | 0.58 | 0.11 | 0.52 | 0.09 | 0.22 | 0.44 | 0.70 | 0.84 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 98.15M | 447.75M | 506.98M | 530.30M | 512.12M | 539.69M | 679.52M | 968.18M |
| Total Equity | 48.36M | 59.92M | 65.29M | 71.11M | 101.17M | 114.24M | 125.66M | 145.51M | 311.96M | 374.25M |
| Long Term Debt | - | - | 0 | 18.53M | 8.28M | 51.37M | 62.89M | 63.91M | 0 | 168.84M |
| Total Liabilities | - | - | 32.86M | 376.64M | 405.80M | 416.05M | 386.46M | 394.18M | 367.56M | 593.93M |
| Current Liabilities | - | - | 29.55M | 51.19M | 89.02M | 71.64M | 70.25M | 71.55M | 101.70M | 147.26M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 17.25M | 23.27M | 9.55M | 50.20M | - | 9.04M | 33.09M | 39.30M | 48.29M |
| Investing Cash Flow | -16.08M | -9.48M | -26.46M | -41.62M | - | -24.24M | -30.22M | -70.68M | -227.97M |
| Financing Cash Flow | -1.16M | -13.79M | 17.27M | -8.95M | - | 12.08M | 1.11M | 49.57M | 172.46M |
| Capital Expenditure | -3.13M | -3.60M | -6.71M | -7.25M | - | -14.17M | -8.11M | -8.99M | -12.04M |
| Free Cash Flow | 14.12M | 19.67M | 2.84M | 42.95M | - | -5.13M | 24.98M | 30.31M | 36.26M |
| Net Change in Cash | - | - | - | - | - | -3.11M | 3.98M | 18.19M | -7.22M |
| Share Buybacks | - | 0 | 0 | 65.00K | 0 | 0 | - | - | - |
| Dividends Paid | 0 | 0 | 11.60M | 0 | 0 | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - |
| Operating Margin % | 6.1% | 7.2% | 1.7% | 4.8% | 1.1% | 2.7% | 4.6% | 5.5% | 5.5% |
| Net Margin % | 3.9% | 5.5% | 0.8% | 4.0% | 0.6% | 1.4% | 2.5% | 3.2% | 3.1% |
| ROE % | 16.5% | 24.0% | 3.6% | 15.6% | 2.4% | 5.3% | 9.2% | 7.2% | 7.9% |
| ROCE % | - | 30.1% | 1.4% | 4.5% | 1.0% | 2.9% | 5.4% | 6.6% | 6.3% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 8.47% | 2.96M | $109.72M |
| 2 | Van Berkom & Associates Inc. | 6.78% | 2.37M | $87.85M |
| 3 | Wasatch Advisors LP | 5.35% | 1.87M | $69.35M |
| 4 | Turtle Creek Asset Management Inc. | 4.91% | 1.71M | $63.57M |
| 5 | Vanguard Capital Management LLC | 4.24% | 1.48M | $54.91M |
| 6 | Paradigm Capital Management | 4.02% | 1.40M | $52.02M |
| 7 | FMR, LLC | 3.38% | 1.18M | $43.83M |
| 8 | Provident Investment Management, Inc. | 2.69% | 939.21K | $34.83M |
| 9 | Goldman Sachs Group Inc | 2.55% | 891.43K | $33.05M |
| 10 | Geode Capital Management, LLC | 2.54% | 886.78K | $32.88M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for PNTG
Senior Health, Home Health & Hospice Stocks Q2 Results: Benchmarking The Pennant Group (NASDAQ:PNTG) - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxPd3hPaTFSMTBtYTcwUm9FMHdtRV8wdjNObDdDSGJFZXY3aHE2MmNWczVKMGtzRHBsamxydmtfclJMV2ZkakNxWVp5OHBLREtXWklmQ3dVdFd5dnlLdEw3VlZVM2cxOW1RdmJOX2taRnIzZDg4WFRnY2FQLWdxb0tCT25MUWFPUUxSZjVrVG…
A healthcare conference will include Pennant's CEO and president in a fireside chat. - Stock Titan
<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxNMnZ2SkdlaHdPd0NaZ1BpcTYxUnFsSjN0Xzc2d0UyRXJMRTdCdGNyU3ppZm5WVE9BMTF2RXZuc1JZMzBwaV9KVmJ4UFVpR3Y2OGliQ0dldmlaNGszQWhuVFFQSHlIaDZycy1RRm9tcXpuWXBKYmFPTGRuVjRHTmk3elE0S3MzQ0ROQmotU0…
What Pennant Group (PNTG)'s Raised Revenue Guidance and Q2 Beat Mean For Shareholders - simplywall.st
<a href="https://news.google.com/rss/articles/CBMizwFBVV95cUxOcnY4OTI2SHAxcUhIZHVjNUR4V3BIeDJWZUlENUtlVGkyekxxUTV3RDR2RXJ3YlUzUnNVREQzc2cweENqZ0ZlYUdfRFJMQXpzbjd5TDBBT0d4R0E5SVBTYWtjYmhzOHNNSDAwYVNFQjdlVkhUQndwdEdyNmxqOE83TzRMcUs4UVlWSmRidj…
(PNTG) Movement as an Input in Quant Signal Sets - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMixAFBVV95cUxPX2RaQkl0OE5nNWMxVFhwQ016RkNsYzFXdkxORGI4OXNSYmp4b3JJRW1hMHFtLWdrLXRhNDk2VF9yMDA4cXJaUmRWSTJIQzRaRHpHb09DeE9ReWpxdTNVYlVGQjFKTjNnbVk4Vl9WQXNoM1pQSlhfOWpPWnNXWlhLVEQ2czh5Rkxsa2s0Yz…
The Pennant Group (PNTG) Stock Rises on Q2 2026 Earnings - quiverquant.com
<a href="https://news.google.com/rss/articles/CBMikwFBVV95cUxON2xMNUt3YkFJVFNwZEFONDZiNDNRTlF1bDZBU3gzc3o0X2h0Skczb1RMdG1QQ3JCNWl6aDFmYmpWdEIxNG5LU3pPSTBZTENrZ09JQURfMXNjMkkxUWhiRWJNN01aMGZza1hCbW1oT3pmNWFVYWxjblZGaW95NXFEQzVjLUxfUnhxcnRNc3…
Pennant Group (PNTG) Stock Faces Margin Scrutiny Behind Stronger Revenue - webull.com
<a href="https://news.google.com/rss/articles/CBMiWEFVX3lxTE1OT2NXdVdib196QmNZZm5kM3JwM2RKT2JNb0tWTmowSE1rRS00eE8zZmxsM2dtRVJ5d0JlZ1k3ek5vTjEzZ1JSd3FSa3lfX3I1RzVhbnkzY0s?oc=5" target="_blank">Pennant Group (PNTG) Stock Faces Margin Scrutiny…
PNTG — Frequently Asked Questions
What is the current share price of The Pennant Group, Inc. (PNTG)?
As of 2026-09-07 16:24 PDT, The Pennant Group, Inc. (PNTG) trades at $38.00 on NasdaqGS. Its 52-week range is $23.64 to $42.02.
What is the market capitalisation of PNTG?
The Pennant Group, Inc. (PNTG) has a market capitalisation of $1.33B on NasdaqGS.
What is the P/E ratio of PNTG?
PNTG trades at a trailing price-to-earnings (P/E) ratio of 41.76. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 3.92.
What is the return on equity (ROE) of PNTG?
PNTG has a return on equity (ROE) of 10.42%. Its return on capital employed (ROCE) is 6.32%.
Is PNTG a good stock to buy?
This page provides a data-driven analysis of The Pennant Group, Inc. (PNTG), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.